ActiveAtlas Opportunity Score 72/100
Texas HHSC Kidney Health Care Program Drug Rebate Agreement — HHS0012325
Texas HHSC is accepting applications through July 1, 2027 at 5:00 PM CDT from qualifying prescription-drug manufacturers for Kidney Health Care Program rebate agreements supporting Texans with end-stage renal disease who receive dialysis or have received a kidney transplant.
FundingNo conventional grant award or contract ceiling is published. The opportunity establishes pharmaceutical rebate agreements for the Texas Kidney Health Care Program.
DeadlineJuly 1, 2027 at 5:00 PM Central Daylight Time (CDT).
Last verifiedSeptember 18, 2026
Required next actionFor a qualifying prescription-drug manufacturer, review the current HHS0012325 Open Enrollment package and Attachment A; confirm an active federal rebate agreement with Texas Medicaid, written KHC product-criteria verification, manufacturer/labeler information, and all required contract and data-security documents before submission.
Broad Eligibility
Specialized manufacturer eligibility. HHSC's required-qualifications attestation requires the applicant manufacturer to be engaged in a federal rebate agreement with Texas Medicaid and to have written verification that its product or products meet KHC program criteria.
Atlas Analysis
Atlas Opportunity Score 72/100. Second-pass healthcare-scope gate PASS. HHS0012325 directly supports the Texas Kidney Health Care Program through pharmaceutical rebate agreements for residents with ESRD who receive dialysis or have had a kidney transplant. Although N9+ Fit is 0/100 and QC Healthcare direct-applicant fit is 0/100, the controlling HHSC source independently documents a direct renal-health and pharmaceutical-reimbursement purpose, so those product/company-fit scores do not negate healthcare scope. The opportunity is current through July 1, 2027 at 5:00 PM CDT and is limited to qualifying manufacturers with a federal rebate agreement with Texas Medicaid and written KHC product-criteria verification. No applicant outreach or CRM/WorkDrive pursuit is appropriate absent a genuinely eligible manufacturer-side use case.
Opportunity Overview
Texas Health and Human Services Commission (HHSC) is operating Open Enrollment HHS0012325 for the Kidney Health Care (KHC) Program Drug Rebate Agreement. KHC is a 100% state-funded State Pharmaceutical Assistance Program serving Texas residents diagnosed with end-stage renal disease (ESRD) who receive kidney dialysis or have had a kidney transplant.
Current Deadline
The current HHSC Open Enrollment page lists a submission deadline of July 1, 2027 at 5:00 PM Central Daylight Time.
Applicant Scope
The open enrollment is for pharmaceutical rebate agreements. HHSC’s required-qualifications attestation states that the applicant manufacturer must be engaged in a federal rebate agreement with Texas Medicaid and must have written verification that its product or products meet KHC program criteria. This is therefore a specialized manufacturer contracting/reimbursement pathway, not a general grant for hospitals, clinics, schools, or community organizations.
Atlas Healthcare-Scope Review
The healthcare-scope gate is satisfied because the contracted reimbursement mechanism directly supports prescription-drug access and medical-expense relief for people with ESRD receiving dialysis or post-transplant care. Atlas second-pass review confirmed the saved record, current HHSC source, actionable status, and nonduplication before publication.
Source verificationOfficial government source · resources.hhs.texas.govAtlas last verified this record September 18, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
